

BAKER BOTTS L.L.P.

30 ROCKEFELLER PLAZA

NEW YORK, NEW YORK 10112-4498

TO WHOM IT MAY CONCERN:

Be it known that WE, YOUNG HOON PARK, a citizen of the Republic of Korea, residing at #111-102, Mujigae Daelim Apt., Gumi-dong, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-703, BYOUNG CHOON LEE, a citizen of the Republic of Korea, residing at #203, 160-28 Anam-dong 5-ga, Seongbuk-gu, Seoul, 136-075, DAE CHEOL KIM, a citizen of the Republic of Korea, residing at #201-302, Hwanggol Maeul Shinmyung Apt., 1054-3 Yeongtong-dong, Paldal-gu, Suzon-si, Gyeonggi-do, 442-747, JIN HO LEE, a citizen of the Republic of Korea, residing at #101-1611, Pungsan Apt., Songjeong-dong, Icheon-si, Gyeonggi-do, 467-711, and JAE YONG CHO, a citizen of Korea, residing at #505-802, Manhyun Maeul Hyndai I'Park, Sanghyun-dong, Yongin-si, Gyeonggi-do, 449-843, have invented an improvement in

tdcBC/pckA GENE-INACTIVATED MICROORGANISM AND METHOD OF
PRODUCING L-THREONINE USING THE SAME

of which the following is a

SPECIFICATION

[0001] This application claims priority to Korean Patent Application No. 10-2003-0021458 filed April 4, 2003, the contents of which are incorporated herein in their entirety by reference

[0002] The present invention relates to an L-threonine-producing microorganism and a method of producing an L-threonine-producing microorganism. More particularly, the present invention relates to a microorganism that contains an inactivated, chromosomal *tdcBC* gene and an inactivated, chromosomal *pckA* gene. Microorganisms of the invention display remarkably improved productivity of L-threonine due to the inactivation of the two genes. Also provided is a method of producing L-threonine using such a microorganism.

BACKGROUND OF THE INVENTION

[0003] L-threonine is known to be an essential amino acid, which has been widely used as an additive to animals' fodder and foods and an animal growth stimulator, as well as a component of medical aqueous solutions and other raw material for medicinal products. L-threonine is currently produced by only five companies in advanced countries, including the Ajinomoto Company in Japan, and is two to three times more expensive than lysine that is known to be highly valuable due to its high price of 5,000-6,000 dollars per ton in the international market. Thus, L-threonine has high growth potential in the world market.

[0004] L-threonine is currently produced by microbial fermentation techniques, using mainly mutants derived from wild types of microorganisms, including *Escherichia coli*, the genus *Corynebacterium*, the genus *Brevibacterium*, the genus *Serratia* and the genus *Providencia*. Examples of these mutants include those having resistance to amino acid analogues or drugs, and their auxotrophs for diamino-pimelic acid, methionine, lysine and isoleucine (Japanese Pat. Publication No. Heisei 2-219582; Korean Pat. Application No. 1998-32951; *Appl. Microbiol. Biotechnol.*, 29:550-553, 1988). However, such mutant strains are disadvantageous in terms of having low L-threonine productivity and being limited to growth on media supplemented with expensive diamino-pimelic acid or isoleucine due to their auxotrophic properties for the diamino-pimelic acid or isoleucine. That is, in the case of using a mutant requiring diamino-pimelic acid for growth, this fermentative production of L-threonine is costly. Likewise, in the case of using an isoleucine auxotroph, a fermentation medium for this auxotroph must be supplemented with expensive isoleucine, resulting in increased production costs of L-threonine.

[0005] These problems may be overcome with an isoleucine-leaky mutant. For example, Korean Pat. Publication No. 92-8365 discloses an isoleucine-leaky mutant that does not need isoleucine in its medium and produces higher levels of L-threonine than known strains. However, this classical mutation method is also time-consuming and ineffective in selecting novel bacterial strains capable of producing high levels of L-threonine. In addition, its greatest disadvantage is being limited in improvement of L-threonine productivity.

[0006] In this regard, instead of employing auxotrophs, other methods for mass production of L-threonine have been developed. These methods employ metabolic engineering techniques to obtain recombinant L-threonine-producing microorganisms that have increased activity of enzymes participating in the biosynthesis of L-threonine. That is, genes corresponding to enzymes involving in L-threonine metabolism are isolated using genetic recombination techniques, cloned into proper gene vehicles, and introduced into microbial mutants to improve L-threonine productivity of the mutants.

[0007] The present inventors previously developed a method of developing a L-threonine producing strain using such metabolic engineering techniques, as disclosed in Korean Pat. Application No. 2001-6976. Briefly, high yields of L-threonine can be achieved by employing a recombinant microorganism comprising (a) one or more chromosomal copies of a *ppc* gene encoding phosphoenol pyruvate carboxylase (hereinafter, referred to simply as "*ppc*"), which catalyzes the formation of oxaloacetate (OAA) from phosphoenol pyruvate (PEP) and (b) an operon including genes encoding aspartokinase 1-homoserine dehydrogenase (*thrA*), homoserine kinase (*thrB*) and threonine synthase (*thrC*), which catalyze the biosynthesis of L-threonine from aspartate.

[0008] L-threonine is synthesized from aspartate by a multi-step pathway, wherein the aspartate is formed from OAA converted by PPC from PEP. L-threonine biosynthesis is inhibited when glucose is present in relatively high levels in media in comparison with the bacterial growth rate and the overall rate of the tricarboxylic acid (TCA) cycle. In this situation, *ppc* gene expression is suppressed, while expression of a gene encoding PEP carboxykinase (hereinafter, referred to simply as "*pckA*"), which catalyzes the conversion of OAA into PEP is increased. The elevated levels of *pckA* result in the formation of PEP from OAA as the precursor for amino acid biosynthesis, wherein other by-products are synthesized from the PEP (Goldie H. Medina V., *Mol. Gen. Genet.*, 220(2):191-196, 1990; Dang et al., *E.coli and Salmonella*, 1:191-102, 1996). Therefore, the *pckA* gene should be essentially inactivated in order to produce L-threonine in high levels by increasing the flux of metabolic pathways responsible for L-threonine synthesis.

[0009] On the other hand, several pathways for L-threonine degradation are known, which include the following three pathways. One involves a pathway initiated by threonine dehydrogenase yielding α -amino- β -ketobutyrate. The α -amino- β -ketobutyrate is either converted to acetyl-CoA and glycine or spontaneously degrades to aminoacetone that is converted to pyruvate. The second pathway involves threonine dehydratase yielding α -ketobutyrate which is further catabolized to propionyl-CoA and finally the TCA cycle intermediate, succinyl-CoA. The third pathway utilizes threonine aldolase (Neidhardt F.C. et al. *Escherichia coli and Salmonella: cellular and molecular biology*, 2nd ed. ASM press. Washington DC, pp369-370). Among them, the threonine dehydratase is an operon that is expressed under hypoxia and high levels of threonine. The present inventors developed a microorganism with improved productivity of L-threonine by specifically inactivating this

operon gene (*tdcBC*) via a genetic recombination technique (Korean Pat. Application No. 2002-015380).

[0010] On the other hand, International Pat. Publication No. WO 02/29080 A2 discloses a method of producing L-threonine using a *pckA* gene-defective microorganism, which is prepared by introducing it into a wild type strain of the microorganism a recombinant vector carrying a partially deleted *pckA* gene. However, this microorganism is problematic with respect to production yield of L-threonine because pathways for degradation and intracellular influx of synthesized L-threonine are still activated in the microorganism.

SUMMARY OF THE INVENTION

[0011] Intensive and thorough research conducted by the present inventors has yielded methods of preparing a microorganisms that are capable of producing high levels of L-threonine, even when grown in a medium containing high concentrations of glucose, without degrading the L-threonine produced. The inventors have found that the problems encountered in the prior art may be overcome with microorganisms in which the endogenous chromosomal *pckA* gene is inactivated and the *tdcBC* operon is knocked out. These microorganisms have improved L-threonine productivity in comparison with the conventional L-threonine-producing microorganisms.

[0012] Therefore, the present invention provides a *pckA* gene-inactivated microorganism, which is prepared by introducing an antibiotic resistance gene into the chromosomal DNA of a parent *E. coli* strain producing high levels of L-threonine, such as an *E. coli* strain containing an inactivated *tdcBC* operon, by a DNA recombination technique. Since its chromosomal *tdcBC* operon is inactivated, the microorganism according to the present invention has the effect of

preventing degradation and intracellular influx of L-threonine. In addition, due to the inactivation of the *pckA* gene involved in the inhibition of L-threonine synthesis, the microorganism of the present invention has more activated pathways for L-threonine biosynthesis. Therefore, the microorganism of the present invention may be useful for mass production of L-threonine because of being capable of producing L-threonine in high levels and high yields even in the presence of high concentrations of glucose.

BRIEF DESCRIPTION OF THE DRAWINGS

[0013] The objects, features and other advantages of the present invention will be more clearly understood from the following detailed description taken in conjunction with the accompanying drawings, in which:

[0014] FIG. 1 is a schematic view showing a process of cloning a *pckA* gene;

[0015] FIG. 2 is a schematic view showing a process of preparing a recombinant microorganism into which a *pckA* gene fragment containing a chloramphenicol resistance gene (*cat*) and *loxP* sites, $\Delta pckA::loxpcat$, is introduced; and

[0016] FIG. 3 is a photograph showing a result of Southern blotting, in which a chloramphenicol resistance gene(*cat*) is identified to be inserted into a *pckA* gene on the chromosome of an L-threonine-producing *E. coli* strain (lane 1: recombinant strain selected in the presence of chloramphenicol according to the present invention; lane 2: parent strain TRN212; and lane 3: size marker).

DETAILED DESCRIPTION OF THE INVENTION

[0017] In order to accomplish the above objects, the present invention provides a novel strain of *E. coli*, in which the wild-type, endogenous, chromosomal *tdcBC* and *pckA* genes have been inactivated.

[0018] In the *tdcBC/pckA* gene-inactivated *E. coli* strain, the *pckA* gene is inactivated by introducing an exogenous *pckA* gene fragment that comprises an antibiotic resistance gene and a site-specific recombinase binding site at each of its ends into an *E. coli* strain containing an L-threonine degradation-associated operon, *tdcBC* that is inactivated, and then allowing homologous recombination to occur between the foreign exogenous *pckA* gene fragment and the wild-type, endogenous, chromosomal *pckA* gene, thereby inactivating the chromosomal *pckA* gene.

[0019] In addition, the present invention provides a method of producing L-threonine using the *tdcBC/pckA* gene-inactivated *E. coli* strain, so produced.

[0020] A strain of *E. coli*, which contains an L-threonine degradation-associated operon specifically inactivated by genetic recombination and has improved productivity of L-threonine due to the inactivation of the operon, may be used as a parent strain in the present invention. A preferred parent strain is *E. coli* strain TRN212 (accession number: KCCM-10353; Korean Pat. Application No. 2002-015380), which was developed by the present inventors.

[0021] The present invention is characterized by preparing a novel *E. coli* strain producing high levels and high yields of L-threonine by inactivating the *pckA* gene involved in inhibition of L-threonine synthesis in a parent *E. coli* strain containing an L-threonine degradation-associated

operon (*tdcBC*) inactivated. The inactivation of both *tdcBC* and *pckA* genes results in the prevention of degradation and intracellular influx of L-threonine, mediated by the gene products of the *tdcBC* operon, and the inhibition of L-threonine synthesis, mediated by a gene product of the *pckA* gene, leading to high level production of L-threonine.

[0022] Therefore, the present invention provides a *tdcBC/pckA* gene-inactivated *E. coli* strain, which is prepared by introducing an exogenous *pckA* gene fragment that comprises an antibiotic resistance gene having a site-specific recombinase binding site at each of both ends into an *E. coli* strain containing an L-threonine degradation-associated operon, *tdcBC*, that is inactivated, and then allowing for homologous recombination between the foreign exogenous *pckA* gene fragment and a *pckA* gene on chromosome to inactivate the chromosomal *pckA* gene.

[0023] In addition, the *pckA* gene on chromosome of the parent *E. coli* strain is inactivated by removal of the antibiotic resistance gene incorporated into the chromosomal *pckA* gene by the activity of the site-specific recombinase expressed in the bacterial strain, and the presence of one copy of a binding site of the site-specific recombinase in the chromosomal *pckA* gene.

[0024] Inactivation of the *pckA* gene on the bacterial chromosome is achieved by homologous recombination with an exogenous *pckA* gene fragment. The foreign *pckA* gene fragment is inactivated by insertion of an antibiotic resistance gene thereinto. This foreign inactivated *pckA* gene fragment is introduced into a parent *E. coli* strain, and double crossover recombination is then allowed to occur between a *pckA* gene on the bacterial chromosome and the foreign inactivated *pckA* gene fragment to inactivate the *pckA* gene on the bacterial chromosome. The presence of the antibiotic resistance gene in the foreign inactivated *pckA* gene facilitates selection of *pckA* gene-inactivated cells.

[0025] According to the present invention, an “exogenous *pckA* gene fragment” may be any portion of the *pckA* gene that is (a) transcriptionally and/or translationally inactive, and/or (b) produces a non-functional gene product. In some embodiments, the exogenous *pckA* gene fragment may comprise up to the full length *pckA* gene, the sequence of which is interrupted by the insertion of another gene or genes, *e.g.* a selection marker such as an antibiotic resistance gene, a pigment, or an autofluorescent protein. In some embodiments, the interrupting gene may be flanked by site-specific recombination sites on both ends. These flanking site-specific recombination sites may or may not be contiguous with the interrupting gene. In some embodiments, the exogenous *pckA* gene fragment originates from the same species or strain of microorganism as the microorganism to be engineered according to the present invention. The sequence of the *pckA* gene fragment preferably has a sequence that is similar enough to the endogenous, wild-type, chromosomal *pckA* gene targeted so as to allow homologous recombination to occur

[0026] Non-limiting examples of the antibiotic resistance gene used in for inactivation of the *pckA* gene include a chloramphenicol resistance gene, a kanamycin resistance gene, a gentamycin resistance gene, and an ampicillin resistance gene.

[0027] On the other hand, after a *pckA* gene-inactivated *E. coli* strain is selected, a site-specific recombinase may be expressed in the selected strain to remove the antibiotic resistance gene incorporated into the bacterial chromosome. That is, the antibiotic resistance gene is incorporated into the *pckA* gene on the bacterial chromosome along with site-specific recombinase binding sites, and removed by the activity of the site-specific recombinase expressed in the bacterial strain. Non-limiting examples of the site-specific recombinase include

FLP, Cre and XerC/D. The removal of the antibiotic resistance gene allows the same antibiotic resistance gene to be used again as a selective marker when another gene of the identical bacterial strain is desired to be inactivated.

[0028] In the present invention, in order to inactivate the chromosomal *pckA* gene, a *pckA* gene fragment containing a chloramphenicol resistance gene, each end of which is linked to a *loxP* site, is used. The *loxP* sites, which are preferably in the same orientation, are recognized by a site-specific recombinase, Cre. The antibiotic resistance gene located between the two *loxP* sites may be excised from the bacterial chromosome by the activity of Cre recombinase expressed in the *E. coli* strain. In some embodiments of the invention, the *loxP* sites may be modified to prevent reintegration of the antibiotic resistance gene according to methods known in the art.

[0029] The Cre recombinase expression in the *E. coli* strain may be achieved by a method known in the art. In the present invention, a plasmid carrying a *cre* gene, pJW168, is introduced into the *E. coli* strain to express Cre enzyme therein.

[0030] In one embodiment of the present invention, a partial *pckA* gene was amplified by PCR using as a template genomic DNA isolated from a L-threonine-producing *E. coli* strain including an inactivated *tdcBC* operon. The amplified partial *pckA* gene was cloned into a pT7Blue vector (Novagen Co.), thus yielding a recombinant vector containing a partial *pckA* gene, pT7Blue/*pckA*. In addition, a DNA fragment containing a chloramphenicol resistance gene and *loxP* sites, *loxpcat2*, was obtained from a *ploxpcat2* plasmid (Beatriz Palmeros et al., Gene, 247:255-264, 2000), and ligated to NruI-digested pT7Blue/*pckA*, thus generating a recombinant plasmid containing a *pckA* gene fragment that contains a chloramphenicol resistance gene and

flanking *loxP* sites, pT7 Δ *pckA::loxpcat*. Therefore, the present invention provides the recombinant plasmid as prepared above, pT7 Δ *pckA::loxpcat*.

[0031] In another embodiment of the present invention, a suitable parental strain for *tdcBC/pckA* gene-inactivated *E. coli* strains of the invention is *E. coli* strain TRN212 having an inactivated *tdcBC* operon. In this parental strain, inactivation of the *tdcBC* operon is accomplished by homologous recombination using a kanamycin resistance gene having a *loxP* site at each of its both ends. To form microorganisms of the present invention, in some embodiments, a *pckA* gene fragment containing a chloramphenicol resistance gene, each end of which is linked to a *loxP* site, was introduced into *E. coli* strain TRN212 containing an inactivated *tdcBC* operon. Then, homologous recombination was allowed to occur between the *pckA* gene on the bacterial chromosome and the exogenous *pckA* gene fragment containing the chloramphenicol resistance gene and the *loxP* sites, thereby yielding a recombinant *E. coli* strain containing inactivated chromosomal *tdcBC* and *pckA* genes. A representative recombinant *E. coli* strain was designated as “FTR2717”, and deposited under the Budapest Treaty at the Korean Culture Center of Microorganisms (KCCM), whose address is Hongje-dong, Seodaemun-gu, Seoul 120-749, on March 20, 2003 and assigned Accession No. KCCM-10475.

[0032] The recombinant *E. coli* FTR2717 strain exhibits the following characteristics:

- (1) it has resistance to threonine analogues, lysine analogues, isoleucine analogues, and methionine analogues compared to a wild type strain thereof;

- (2) its chromosome contains an endogenous *ppc* gene and an endogenous threonine operon containing *thrA*, *thrB* and *thrC* genes as well as one or more copies of an exogenous *ppc* gene and exogenous *thrA*, *thrB* and *thrC* genes;
- (3) it includes an operon gene involved in L-threonine degradation, *tdcBC*, which is inactivated; and
- (4) it includes a *pckA* gene involved in inhibition of L-threonine synthesis, which is inactivated, so that it produces high levels of L-threonine under a high concentration of glucose in a medium.

[0033] In some embodiments, *tdcBC/pckA* gene-inactivated *E. coli* strains of the invention produce about 1% more, about 2% more, about 3% more, about 4% more, about 5% more, about 6% more, about 7% more, about 8% more, about 9% more, about 10% more, about 11% more, about 12% more, or about 13% more L-threonine than (a) a parent strain of *Escherichia coli* or (b) a corresponding wild-type strain of *Escherichia coli* cultured under substantially the same conditions. In some embodiments, *tdcBC/pckA* gene-inactivated *E. coli* strains of the invention produce about 6.5% more or about 13% more L-threonine than (a) a parent strain of *Escherichia coli* or (b) a corresponding wild-type strain of *Escherichia coli* cultured under substantially the same conditions.

[0034] A better understanding of the present invention may be obtained through the following examples which are set forth to illustrate, but are not to be construed as the limit of the present invention.

EXAMPLES

EXAMPLE 1: Cloning of pckA gene

[0035] A recombinant vector carrying a *pckA* gene was prepared (see, FIG. 1). First, bacterial genomic DNA was isolated from a L-threonine-producing *E. coli* strain TRN212 (accession number: KCCM-10353), having an inactivated *tdcBC* operon, using a QIAGEN Genomic-tip system (QIAGEN Co.). Using the isolated genomic DNA as a template, PCR was carried out to amplify a region of the *pckA* gene of about 1.5-kb. The PCR included a forward primer having the sequence of SEQ ID NO:1 and a reverse primer having the sequence of SEQ ID NO:2. Amplification proceeded for 30 cycles wherein each cycle consisted of denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and extension at 72°C for 90 seconds.

[0036] The PCR products were size-fractionated on a 0.8% agarose gel, and a 1.5-kb band was excised out from the gel. From the excised band, a 1.5-kb DNA fragment was purified using a DNA Gel Purification Kit (QIAGEN Co.), and cloned into an EcoRV-digested pT7Blue vector (Novagen Co.) by blunt end ligation at 16°C. This yielded a recombinant vector containing a partial *pckA* gene, pT7Blue/*pckA*. Then, an *E. coli* NM522 strain was transformed with the pT7Blue/*pckA*, and streaked on a solid medium (LB: 1% NaCl, 1% Tryptone, 0.5% Yeast extract) containing ampicillin (100 mg/L), followed by incubation at 37°C overnight. Colonies grown on the solid medium were used to inoculate liquid medium containing ampicillin, (3 mL each) followed by incubation at 37°C overnight. Plasmid DNA was isolated from the cultured bacteria using a QIAGEN mini prep kit (QIAGEN Co.), and analyzed for its size. Also, orientation of the *pckA* gene was analyzed by restriction mapping with NruI and StuI. Thereafter, the plasmid DNA was digested with NruI, and size-fractionated on a 0.7% agarose

gel. A slice of the gel at about 4.3-kb was excised and a 4.3-kb DNA fragment was purified from the gel slice.

EXAMPLE 2: Construction of recombinant vector carrying an inactivated pckA gene and preparation of pckA gene-inactivated E. coli strain

2-1) Construction of a recombinant vector carrying an inactivated pckA gene

[0037] A 1.2-kb DNA fragment, loxpcat, which contains a chloramphenicol resistance gene having a *loxP* site at each of its both ends was obtained by digesting with HincII a ploxpcat2 plasmid (plasmid carrying a chloramphenicol resistance gene having *loxP* sites at its both ends; Beatriz Palmeros et al., *Gene*, 247:255-264, 2000, Professor G. Gosset, University of Mexico). The 1.2-kb DNA fragment was ligated to the NruI-digested pT7Blue/*pckA* prepared in Example 1 by blunt end ligation, thus yielding an about 5.7-kb recombinant vector containing an inactivated *pckA* gene, pT7 Δ *pckA*::loxpcat (see, FIG. 2).

2-2) Preparation of a pckA gene-inactivated E. coli strain

[0038] The pT7 Δ *pckA*::loxpcat recombinant vector, prepared in Example 2-1), was introduced into an *E. coli* NM522 strain. The transformed NM522 strain was streaked on a solid medium (LB: 1% NaCl, 1% Tryptone, 0.5% Yeast extract) containing ampicillin and chloramphenicol, followed by incubation at 37°C overnight. The colonies grown on the solid medium were inoculated in 3 mL of a liquid medium containing ampicillin and chloramphenicol, followed by incubation at 37°C overnight. Plasmid DNA was isolated from the cultured bacteria using a QIAGEN mini prep kit, and analyzed for its size and orientation of the inserted *pckA* gene. Thereafter, the plasmid DNA was double-digested with PstI and KpnI, and size-

fractionated on a 0.7% agarose gel. A slice of the gel at about 2.7-kb was excised and a 2.7-kb DNA fragment ($\Delta pckA::loxpcat$) was purified from the gel slice.

[0039] The *pckA* gene fragment containing a chloramphenicol resistance gene having *loxP* sites at its both ends, $\Delta pckA::loxpcat$, was introduced into a L-threonine-producing *E. coli* strain, TRN212 (accession number: KCCM-10353), by electroporation. Thereafter, the transformed TRN212 strain was streaked on a solid medium containing sufficient chloramphenicol to select only chloramphenicol-resistant cells, *i.e.* to select cells wherein a *pckA* gene on chromosome was replaced with the foreign *pckA* gene fragment ($\Delta pckA::loxpcat$). The selected clones were evaluated for whether the chromosomal *pckA* gene is specifically knocked out, by Southern blot analysis according to the same method as in Example 3, below.

[0040] Clones identified as having a *pckA* gene specifically knocked out were transformed with a pJW168 plasmid (gift from Prof. Guillermo Gosset at the University of Mexico) that contains a *cre* gene encoding a site-specific recombinase recognizing *loxP* sites. The transformed cells were cultured in a culture medium containing 10 mM L-arabinose overnight. These conditions permit site-specific recombination to occur, resulting in the removal of the chloramphenicol resistance gene incorporated into the bacterial chromosome. Then, the culture fluid was diluted 10^7 -fold and spread on a solid LB medium supplemented with ampicillin (100 mg/L), followed by incubation at 30°C overnight. Each of 100 colonies grown on the solid medium was inoculated in 3 mL of each of LB liquid media containing ampicillin or not, followed by incubation at 30°C overnight. Colonies that were killed in the medium containing chloramphenicol but survived in the medium not containing chloramphenicol were determined.

In this selection, only clones having a deletion of the chloramphenicol resistance gene were selected.

EXAMPLE 3: Evaluation of knock-out of pckA gene on chromosome by Southern blotting

[0041] The parental TRN212 strain and one of the chloramphenicol-resistant clones selected in Example 2-2) were cultured overnight in 3 mL of a liquid medium containing chloramphenicol (15 mg/L). Then, genomic DNA was isolated from the culture cells using a QIAGEN genomic kit 20, and was digested with EcoRV overnight. The resulting DNA fragments were separated on a 0.7% agarose gel according to their size. After electrophoresis, the separated DNA fragments were transferred onto a nylon membrane (Biodyne B membrane, Young Sci.) overnight by capillary transfer (Molecular Cloning, Vol 1., pp6.31-6.38). The membrane was dried and then exposed to an UV light (120 mJ/cm², SpectroLinker™) to immobilize the DNA fragments on the membrane (Molecular Cloning, Vol 1., pp6.45). The resulting membrane was incubated in a prehybridization solution I (Roche #1093657) at 55°C for 2 hours, and hybridized with a denatured DNA probe overnight in a hybridization oven (BAMBINO 230300) at 55°C.

[0042] The DNA probe was prepared as follows. First, a ploxpcat2 plasmid was isolated using a QIAGEN kit and digested with HincII to yield a DNA fragment (about 1.2 kb) containing a chloramphenicol resistance gene having a *loxP* site at each of its both ends. The 1.2-kb fragment was boiled in water for 5 minutes and quick-cooled on ice, thus yielding a single-stranded DNA. The single-stranded DNA was then labeled with DIG-UDP using a DIG Labeling and Detection Kit (Roche #1093657) by incubation at 37°C overnight.

[0043] After hybridization, the membrane was washed with washing solutions I and II (Roche #1093657) to remove non-specifically attached DNA molecules. The washed membrane was

masked using a prehybridization solution II (Roche #1093657) at room temperature for 30 minutes, and then reacted with an anti-DIG antibody specifically binding to DIG-UTP at room temperature for 30 minutes. The membrane was washed with a washing solution III (Roche #1093657) to remove non-specifically attached anti-DIG antibodies, and developed using a Labeling and Detection Kit (Roche #1093657) at room temperature until bands were emerged. The results are given in FIG. 3.

[0044] As shown in FIG. 3, in case of the parent strain TRN212, no band was detected (lane 2) because the TRN212 strain did not contain a chloramphenicol resistance gene. In contrast, the chloramphenicol-resistant clone selected according to the present invention showed an about 3.6-kb band (lane 1). These results indicate that the selected clones contain a chloramphenicol resistance gene on its chromosome.

EXAMPLE 4: Comparison of the selected clones for production yields of L-threonine upon culturing in Erlenmeyer flasks

[0045] Among the finally selected recombinant *E. coli* clones of Example 2-2) in which the introduced chloramphenicol resistance gene was removed, thirty clones were evaluated for L-threonine productivity. Each of them was cultured in an Erlenmeyer flask containing a culture medium prepared according to the composition listed in Table 1, below. Then, each culture fluid was evaluated for L-threonine yield. In brief, after each of the thirty clones were grown on a LB solid medium at 32°C, one loop of a single colony for each clone was inoculated in 25 mL of the culture medium and cultured at 32°C for 48 hours at 250 rpm. After each of the culture fluids was centrifuged, the supernatant was 250-fold diluted with distilled water. L-threonine

concentration in the diluted supernatant was measured by HPLC. The results are given in Table 2, below.

TABLE 1

Nutrients	Amount per 1 L
Glucose	70 g
Ammonium sulfate	28 g
KH ₂ PO ₄	1.0 g
MgSO ₄ ·7H ₂ O	0.5 g
FeSO ₄ ·7H ₂ O	5 mg
MnSO ₄ ·8H ₂ O	5 mg
Calcium carbonate	30 g
L-methionine	0.15 g
Yeast extract	2 g
pH (7.0)	

TABLE 2

The number of clones	2	5	14	9
Production yield of L-threonine (g/L)	20-23	23-24.5	24.5-26	>26

[0046] The parent strain TRN212 showed a L-threonine production yield of 23 g/L. Among the thirty tested clones, twenty-eight were found to have better productivity of L-threonine than the TRN212 strain, as shown in Table 2. In particular, nine clones showed a L-threonine production yield higher than 26 g/L, which was about 13.04% higher than the yield of the

TRN212 strain. Among the thirty clones, one clone with the highest yield of L-threonine (over 26 g/L) was selected and designated as "FTR2717 (accession number: KCCM-10475)".

DOCUMENTS CITED

[0047] All sequences, publications, patents, patent applications or other published documents cited anywhere in this specification are herein incorporated in their entirety by reference to the same extent as if each individual sequence, publication, patent, patent application or other published document was specifically and individually indicated to be incorporated by reference.